News in Numbers

$1.05bn

AstraZeneca signed a definitive agreement to acquire rare endocrine disease specialist Amolyt Pharma for $1.05bn in March.

13

The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has already awarded 13 positive opinions on new medicines this year, as per a February 2024 update.

$1bn

GlobalData’s patient-based forecasts estimate that Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), the first-ever therapy approved to treat noncirrhotic nonalcoholic steatohepatitis (NASH), will earn $1bn in 2027.

3 billion

As per a new study highlighted by the World Health Organization, more than 3 billion people were living with a neurological condition in 2021.

85.7%

After news of Amylyx Pharmaceuticals’ Phase III trial for its amyotrophic lateral sclerosis (ALS) therapy Relyvrio (sodium phenylbutyrate and taurursodiol) failing to meet any of its endpoints broke, the company’s stock opened at an 85.7% drop compared to the previous day.

Go to article: Home | What’s next for AAV gene therapies in 2024?Go to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: phasetwoGo to article: Avenga Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: Zenatek Company InsightGo to article: Simtra BioPharma SolutionsGo to article: In DepthGo to article: What’s Next for AAV Gene Therapies in 2024?Go to article: Traceability technologies tighten supply chain fakeryGo to article: Switching sales: Investigating the financial impacts of FDA’s priority vouchersGo to article: Is HIV-TB coinfection treatment entering a new frontier?Go to article: Patient organisations need to tackle transparency Go to article: AD/PD 2024: Eli Lilly’s donanemab hit with FDA delay Go to article: Q&A: Increasing awareness around digital therapeutics key to realising full potentialGo to article: Sponsored SupplementsGo to article: Lactalis IngredientsGo to article: BEA TechnologiesGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue